Literature DB >> 20084164

Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope.

Ben M Chue1.   

Abstract

Entities:  

Year:  2009        PMID： 20084164      PMCID： PMC2806805     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  31 in total

Review 1.  In vitro drug resistance versus chemosensitivity: two sides of different coins.

Authors:  John P Fruehauf; David S Alberts
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

2.  "Will weekly work"? Seems to be so....

Authors:  Andrew D Seidman
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Taming vessels to treat cancer.

Authors:  Rakesh K Jain
Journal:  Sci Am       Date:  2008-01       Impact factor: 2.142

4.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Authors:  Yuval Shaked; Urban Emmenegger; Shan Man; Dave Cervi; Francesco Bertolini; Yaacov Ben-David; Robert S Kerbel
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

5.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

Authors:  V T Smit; A J Boot; A M Smits; G J Fleuren; C J Cornelisse; J L Bos
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

6.  Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.

Authors:  Wei-Shu Wang; Jen-Kou Lin; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Huann-Sheng Wang; Tzeon-Jye Chiou; Jin-Hwang Liu; Chueh-Chuan Yen; Po-Min Chen
Journal:  Oncologist       Date:  2007-03

7.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

Authors:  Stefano Cascinu; Vincenzo Catalano; Luigi Cordella; Roberto Labianca; Paolo Giordani; Anna Maria Baldelli; Giordano D Beretta; Emilio Ubiali; Giuseppina Catalano
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

8.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.

Authors:  Laurence Gamelin; Michele Boisdron-Celle; Remy Delva; Véronique Guérin-Meyer; Norbert Ifrah; Alain Morel; Erick Gamelin
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531
View more
  8 in total

1.  Long-term survival for pancreatic cancer: a matter of hope, courage, or genetics?

Authors:  C Peugniez; Ph Vennin; A Adenis
Journal:  Gastrointest Cancer Res       Date:  2011-03

2.  Methylseleninic acid suppresses pancreatic cancer growth involving multiple pathways.

Authors:  Lei Wang; Hongbo Hu; Zhe Wang; Hua Xiong; Yan Cheng; Joshua Dezhong Liao; Yibin Deng; Junxuan Lü
Journal:  Nutr Cancer       Date:  2014-01-21       Impact factor: 2.900

3.  Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.

Authors:  Pauline Rochefort; Audrey Lardy-Cleaud; Matthieu Sarabi; Françoise Desseigne; Anne Cattey-Javouhey; Christelle de la Fouchardière
Journal:  Oncologist       Date:  2019-06-04

4.  Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry.

Authors:  Raffi Kotoyan; Tiffany Metzger; Cliff Tatum; Ken Robbins; Robert C G Martin
Journal:  J Oncol       Date:  2012-02-15       Impact factor: 4.375

5.  Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis.

Authors:  William H Isacoff; Howard A Reber; Rudolph Bedford; William Hoos; Lola Rahib; Alexander Upfill-Brown; Timothy Donahue; O Joe Hines
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

6.  Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.

Authors:  Ben Man-Fai Chue; Bryce Douglas La Course
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 7.  Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma.

Authors:  Olga Wysocka; Julita Kulbacka; Jolanta Saczko
Journal:  Prz Gastroenterol       Date:  2016-07-22

8.  Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years).

Authors:  Ben Man-Fai Chue; Bryce Douglas La Course
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.